Cochrane · systematic review · CD013382
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Gijtenbeek, RGP, de Jong, K, Venmans, BJW, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 4 · 57.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Platinum doublet compared to non‐platinum therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Population: people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Platinum doublet vs non‐platinum therapy | HR 0.67 [0.57, 0.78] | 7 studies · 697 participants | Moderate Downgraded: risk of bias |
12‐month survival rates Platinum doublet vs non‐platinum therapy | RR 0.92 [0.87, 0.97] | 11 studies · 1567 participants | Moderate Downgraded: risk of bias |
Progression‐free survival Platinum doublet vs non‐platinum therapy | HR 0.57 [0.42, 0.77] | 5 studies · 487 participants | Moderate Downgraded: risk of bias |
Tumor response rate Platinum doublet vs non‐platinum therapy | RR 2.25 [1.67, 3.05] | 9 studies · 964 participants | Moderate Downgraded: risk of bias |
Toxicity – anemia grade 3–5 Platinum doublet vs non‐platinum therapy | RR 1.98 [1, 3.92] | 8 studies · 935 participants | Low Downgraded: risk of bias, inconsistency |
Toxicity – neutropenia grade 3–5 Platinum doublet vs non‐platinum therapy | RR 2.75 [1.3, 5.82] | 8 studies · 935 participants | Low Downgraded: risk of bias, inconsistency |
Toxicity – thrombocytopenia grade 3–5 Platinum doublet vs non‐platinum therapy | RR 3.96 [1.73, 9.06] | 8 studies · 935 participants | Low Downgraded: risk of bias, inconsistency |